Medicare Enrolled

Dr. Matthew Levine, M.D

Endocrinology · La Jolla, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
9898 GENESEE AVE, La Jolla, CA 92037
8588245000
In practice since 2006 (19 years)
NPI: 1801994231 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Levine from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Levine? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Levine

Dr. Matthew Levine is an endocrinology specialist in La Jolla, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Levine performed 2,301 Medicare services across 648 unique beneficiaries.

Between the years covered by Open Payments, Dr. Levine received a total of $190,325 from 52 pharmaceutical and/or device companies across 907 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Levine is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 27% volume in CA $190,325 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,301
Medicare services
Top 27% in CA for endocrinology
648
Unique beneficiaries
$43
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~121 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 1,380 $17 $73
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
501 $96 $350
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
100 $124 $453
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
99 $12 $46
Continuous glucose monitoring with interpretation
This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results.
94 $28 $112
Ultrasound of head and neck soft tissue
This procedure uses sound waves to create images of the soft tissues in the head and neck area. It allows for the visualization of structures beneath the skin without using radiation.
72 $86 $660
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
55 $68 $248
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$190,325
Total received (2018-2024)
Avg $27,189/year across 7 years
Top 3% in CA for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
907
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$178,249 (93.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,580 (4.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,496 (1.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$8,770
2023
$8,576
2022
$20,022
2021
$23,607
2020
$24,750
2019
$39,622
2018
$64,977

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$7,557
AstraZeneca Pharmaceuticals LP
$184
Boehringer Ingelheim Pharmaceuticals, Inc.
$156
Kyowa Kirin, Inc.
$86
Xeris Pharmaceuticals, Inc.
$82
SANOFI-AVENTIS U.S. LLC
$77
Verity Pharmaceuticals Inc.
$66
Alexion Pharmaceuticals, Inc.
$60
Novartis Pharmaceuticals Corporation
$57
Radius Health, Inc.
$50
Mannkind Corporation
$46
Lilly USA, LLC
$43
Amgen Inc.
$42
BETA BIONICS, INC.
$41
Antares Pharma, Inc.
$41
Medtronic, Inc.
$31
Bayer Healthcare Pharmaceuticals Inc.
$24
Tandem Diabetes Care, Inc.
$22
SUN PHARMACEUTICAL INDUSTRIES INC.
$19
Chiesi USA, Inc.
$19
ViiV Healthcare Company
$18
CeQur Corporation
$16
Acella Pharmaceuticals, LLC
$16
Ascensia Diabetes Care Us Inc.
$15
Top 3 companies account for 90.1% of 2024 payments
All-time payments by company (2018-2024) ›
Novo Nordisk Inc
$127,131
Lilly USA, LLC
$24,745
Janssen Pharmaceuticals, Inc
$10,967
Merck Sharp & Dohme Corporation
$7,752
Boehringer Ingelheim Pharmaceuticals, Inc.
$6,336
Amgen Inc.
$3,940
AstraZeneca Pharmaceuticals LP
$2,370
Mannkind Corporation
$2,346
SANOFI-AVENTIS U.S. LLC
$1,024
Insulet Corporation
$327
Dexcom, Inc.
$304
AbbVie, Inc.
$290
MannKind Corporation
$286
Abbott Laboratories
$236
Becton, Dickinson and Company
$228
Alexion Pharmaceuticals, Inc.
$177
Antares Pharma, Inc.
$168
Corcept Therapeutics
$162
Radius Health, Inc.
$135
Kyowa Kirin, Inc.
$107
Shire North American Group Inc
$104
Xeris Pharmaceuticals, Inc.
$101
Companion Medical, Inc.
$88
Novartis Pharmaceuticals Corporation
$84
Ascensia Diabetes Care Us Inc.
$77
Tandem Diabetes Care, Inc.
$71
Valeritas, Inc.
$67
Verity Pharmaceuticals Inc.
$66
GlaxoSmithKline, LLC.
$53
Medtronic, Inc.
$49
Horizon Therapeutics plc
$48
BETA BIONICS, INC.
$41
Aytu BioScience, Inc
$40
Ipsen Biopharmaceuticals, Inc
$40
Bayer HealthCare Pharmaceuticals Inc.
$32
Ascendis Pharma Inc
$32
IBSA Pharma Inc.
$30
Takeda Pharmaceuticals U.S.A., Inc.
$29
Bayer Healthcare Pharmaceuticals Inc.
$24
Ultragenyx Pharmaceutical Inc.
$23
DEXCOM, INC.
$20
SUN PHARMACEUTICAL INDUSTRIES INC.
$19
Chiesi USA, Inc.
$19
VistaPharm, Inc.
$19
ViiV Healthcare Company
$18
Acerta Pharma LLC
$18
CeQur Corporation
$16
Acella Pharmaceuticals, LLC
$16
PFIZER INC.
$14
AbbVie Inc.
$13
Janssen Scientific Affairs, LLC
$13
Collegium Pharmaceutical, Inc.
$12
Top 3 companies account for 85.6% of all-time payments
Associated products mentioned in payments ›
AFREZZA · Aimovig · Androgel · BAQSIMI · BASAGLAR · BD NANO · BD Nano · BD Nano 2nd Gen Pen Needle · BYDUREON · CABENUVA · CRYSVITA · CeQur Simplicity · Cequa · Creon · DEXCOM CGM · DEXCOM G6 CGM SYSTEM · DEXCOM G6 TRANSMITTER · Dexcom CGM · Dexcom G6 Transmitter · EVENITY · EVERSENSE 365 SENSOR KIT (RETAIL) · FARXIGA · FORTEO · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre 2 · FreeStyle Libre blood glucose Flash Monitoring System · GVOKE HYPOPEN · GVOKE PFS · HUMALOG · HUMULIN · HUMULIN R 500 · INTELLIS ADAPTIVESTIM · INVOKANA · InPen · JANUVIA · JARDIANCE · KRYSTEXXA · Kerendia · Korlym · LEQVIO · LOKELMA · LYRICA · LYUMJEV · MINIMED 780G · MOUNJARO · MYCAPSSA · NATPARA · NATPARA (PARATHYROID HORMONE) · NP Thyroid 60 · Natesto · OTREXUP · Omnipod · Otrexup · Ozempic · PNEUMOVAX 23 · PRALUENT · Prolia · RECORLEV · RYBELSUS · Repatha · Rybelsus · SHINGRIX · SOLIQUA · SOLIQUA 100/33 · STEGLATRO · STEGLUJAN · STRENSIQ · SYNJARDY · SYNTHROID · Somatuline Depot · Strensiq · Synthroid · TEPEZZA · TLANDO · TOUJEO · TRADJENTA · TRIJARDY XR · TRULICITY · TZIELD · Thyquidity · Tirosint · Tlando · Tresiba · Trintellix · Tymlos · V-GO · Victoza · Wegovy · XARELTO · XTAMPZA · XYOSTED · iLet Bionic Pancreas · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 3% for endocrinology in CA.

Looking for an endocrinology specialist in La Jolla?
Compare endocrinologists in the La Jolla area by procedure volume, costs, and industry payment transparency.
Browse endocrinologists nearby

Geographic Context

Endocrinologists within 10 mi
94
Per 100K population
2.9
County median income
$102,285
Nearest hospital
SCRIPPS MEMORIAL HOSPITAL LA JOLLA
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Levine is a clinical cardiology specialist, with above-average Medicare volume (top 27% in CA), with speaking/promotional industry engagement in the top 3% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Levine experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Levine performed 1,380 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Levine receive payments from pharmaceutical companies?
Yes. Dr. Levine received a total of $190,325 from 52 companies across 907 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Levine's costs compare to other endocrinologists in La Jolla?
Dr. Levine's average Medicare payment per service is $43. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Levine) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →